Children's Oncology Group
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Children's Oncology Group sits in the top decile of US sponsors by registered trial count (#104 of 15,742 sponsors by registered trial count).
Children's Oncology Group: 342 sponsored US clinical trials, 33 recruiting.
Children's Oncology Group sponsors 342 registered US clinical trials on ClinicalTrials.gov, 33 of them currently recruiting, and 260 completed. 103 of these trials are in Phase 3-4 (later-stage) and 128 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Leukemia, with 12 trials.
Top-decile sponsor footprint
Children's Oncology Group ranks in the top decile of sponsors by registered trial count (#104 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
260 of 262 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (99.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
342 total, page 4 of 7
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
NCT00866918
Study of Blood Samples From Newborns With Down Syndrome
NCT00959283
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)
NCT00866307
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
NCT00653068
Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA])
NCT01119560
Study of Blood Samples From Patients With Osteosarcoma
NCT00954473
Study of Specimens From Young Patients With Neuroblastoma
NCT00958659
Studying Tumor Samples From Young Patients With Neuroblastoma
NCT00907920
Study of Tumor Samples From Patients With Ewing Sarcoma
NCT00898053
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
NCT00742924
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
NCT00671034
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
NCT00716976
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers
NCT00690469
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
NCT00554788
Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
NCT00618813
Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia
NCT00537030
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
NCT00899990
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma
NCT00899275
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer
NCT00674193
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00557193
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
NCT00070109
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
NCT00553202
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
NCT00450450
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
NCT00567567
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
NCT00467051
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
NCT00336024
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
NCT00499616
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00469859
Study of DNA in Blood Samples From Patients With Neuroblastoma
NCT00898391
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
NCT00304070
Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
NCT00470275
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
NCT00458887
Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma
NCT00072384
Collecting and Storing Tissue From Young Patients With Cancer
NCT00898755
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
NCT00382109
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
NCT00369317
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
NCT00381680
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
NCT00372619
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
NCT00346164
Pharmacokinetics of Daunorubicin in Young Patients With Cancer
NCT00673257
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
NCT00436852
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
NCT00437060
Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor
NCT00085098
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
NCT00354835
Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions
NCT00436696
Radiation Therapy in Treating Young Patients With Gliomas
NCT00238264
Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma
NCT00900250
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
NCT00897325
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00372593
High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
NCT00354744
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 75 |
| Phase 3 | 103 |
Therapeutic Areas
What is open in the Children's Oncology Group pipeline
33 recruiting of 342 indexed (10% open); 260 completed (76%).
Phase mix: 103 late (III/IV) vs 128 early (I/II) (balanced across stages).
Top condition: Leukemia (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Children's Oncology Group: open-pipeline peers nationwide
Peers matched on 342 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Children's Oncology Group sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 342 trials (± recruiting share)
- National Institute of Mental Health (NIMH) · 343 trials · 12% recruiting
- Ohio State University Comprehensive Cancer Center · 341 trials · 23% recruiting
- Montefiore Medical Center · 345 trials · 19% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Children's Hospitals and Clinics of Minnesota · 10% recruiting · 31 trials
- Cytokinetics · 10% recruiting · 31 trials
- Sanofi · 10% recruiting · 713 trials
- Joslin Diabetes Center · 10% recruiting · 73 trials
Related
What to do with this Children's Oncology Group page
342 registered trials is a research-attention snapshot, not an endorsement of Children's Oncology Group or any single study.
- 33 of Children's Oncology Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Leukemia is the condition Children's Oncology Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Children's Oncology Group pipeline card: 342 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.